Gene Silencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product & Service (RNAi, CRISPR-Cas9, Antisense Oligonucleotides, Others), By Application (Neurology, Oncology, Infectious Diseases, Metabolic Diseases, Therapeutics Manufacturing, Others), By Region and Competition, 2020-2030F

Market Overview

Global Gene Silencing Market was valued at USD 2.86 Billion in 2024 and is expected to reach USD 4.36 Billion by 2030 with a CAGR of 7.48% during the forecast period. The global gene silencing market is experiencing robust growth, driven by advancements in molecular biology, increasing interest in precision medicine, and the rising need for effective treatments targeting genetic diseases. Gene silencing, a powerful technique used to down regulate or inhibit the expression of specific genes, has emerged as a vital tool in the development of therapies for a wide range of conditions, including cancer, viral infections, and neurological disorders. With the expansion of research activities and the growing understanding of gene function, the market is poised to play a transformative role in healthcare and drug development.

One of the primary drivers of the gene silencing market is the increasing demand for targeted therapies that can address genetic and molecular causes of diseases. Technologies such as RNA interference (RNAi) and antisense oligonucleotides (ASOs) are being used to selectively silence disease-causing genes, providing a more precise and effective approach to treatment. This is particularly significant in oncology, where gene silencing techniques are being developed to target specific oncogenes, paving the way for personalized cancer therapies.

Despite the promising potential of gene silencing technologies, there are challenges that may impact market growth. One of the main challenges is the complexity of delivering gene-silencing molecules to the appropriate tissues without triggering an immune response or causing off-target effects. Additionally, the high costs associated with developing and manufacturing gene silencing therapies could limit accessibility, especially in developing regions.

Key Market Drivers

Growth in Healthcare Industry

With the healthcare industry increasingly shifting towards personalized and targeted treatments, gene silencing technologies like RNA interference (RNAi) and antisense oligonucleotides (ASOs) are gaining traction. Double-stranded RNA-mediated interference (RNAi) offers an efficient and fast approach to suppressing gene expression across various organisms. This gene silencing occurs through the degradation of RNA into short fragments, which then activate ribonucleases to specifically target homologous mRNA. The phenotypic outcomes either mirror those observed in genetic null mutants or resemble a spectrum of allelic mutations. These therapies offer the ability to silence specific disease-causing genes, providing a highly targeted approach to treatment. This is especially important in areas like oncology, where traditional therapies often have limited efficacy and can cause significant side effects. Gene silencing enables more precise interventions, minimizing damage to healthy cells and improving patient outcomes.

The growing incidence of genetic disorders and rare diseases is also driving the demand for gene silencing solutions. Thalassaemia, sickle-cell anaemia, and glucose-6-phosphate dehydrogenase (G6PD) deficiency are among the most prevalent single-gene disorders worldwide. The epidemiology of these conditions varies significantly both within and between countries. This complexity is further heightened by the pronounced molecular and clinical heterogeneity of thalassaemia and sickle-cell anaemia. Many of these conditions are caused by single-gene mutations, making them ideal candidates for gene silencing therapies. As a result, pharmaceutical companies are increasingly investing in the development of gene-silencing-based drugs, spurring growth in the global market.

Surge in Technological Advancements

The surge in technological advancements has become a key driver of the global gene silencing market, as innovative technologies in molecular biology, genetic engineering, and biotechnology have revolutionized the ability to selectively suppress gene expression. The International Union of Biochemistry and Molecular Biology (IUBMB) brings together biochemists and molecular biologists from 77 countries and regions. It actively supports the advancement of research and education globally, with a particular focus on countries where the field is still in the early stages of development. Gene silencing, which involves the inhibition of specific gene activity, has gained significant attention in the medical and research fields due to its potential for treating genetic disorders, cancer, viral infections, and other diseases linked to aberrant gene expression.

One of the primary technological drivers of this market is the development of RNA interference (RNAi) technology, which allows for precise gene silencing by targeting and degrading messenger RNA (mRNA) molecules before they can produce harmful proteins. RNAi-based therapies have opened new avenues for treating diseases caused by genetic mutations or overexpressed genes, offering a targeted approach to gene regulation that minimizes side effects compared to conventional therapies. The growing adoption of RNAi technologies, such as small interfering RNA (siRNA) and microRNA (miRNA), has significantly boosted the market, as they provide efficient and scalable solutions for silencing genes in both research and therapeutic contexts.

Download Free Sample Report

Key Market Challenges

Limited Delivery Mechanisms

One of the primary obstacles in the delivery of gene-silencing molecules is navigating the complex biological barriers within the human body. For these agents to be effective, they must reach the intended cells in sufficient quantities while avoiding degradation by enzymes or elimination by the immune system. The body’s natural defense mechanisms, such as nucleases that degrade RNA and other foreign molecules, pose a major challenge to ensuring that gene-silencing agents remain intact and functional until they reach their target.

Achieving target-specific delivery is another challenge that limits the widespread use of gene silencing therapies. For these therapies to be effective, they must selectively target and silence disease-causing genes without affecting healthy tissues. Current delivery mechanisms often struggle with precision, leading to the potential for off-target effects, which can result in unintended gene silencing and harmful side effects. This lack of specificity reduces the overall efficacy and safety of gene silencing therapies, making it difficult to translate promising laboratory results into clinical success.

Key Market Trends

Increasing Focus on RNA-Based Therapies

RNA interference (RNAi) and antisense oligonucleotides (ASOs) are two key RNA-based approaches that have gained significant attention in recent years. As of today, there are 18 clinically approved RNA-based therapeutics, including two vaccines that brought mRNA into widespread public awareness during the COVID-19 pandemic. From these vaccines to siRNAs and antisense oligonucleotides, RNA therapeutics are being used to address both global pandemics and the rarest of diseases affecting individual patients. Once considered a niche field, RNA therapeutics has now become a mainstream approach in drug discovery and development, with hundreds of new RNA-based treatments in preclinical and clinical pipelines targeting a wide array of diseases. RNAi works by degrading specific messenger RNA (mRNA) molecules, preventing them from being translated into disease-causing proteins, while ASOs bind to mRNA to block its translation or trigger its degradation. These mechanisms enable precise control over gene expression, offering the potential to target diseases at their genetic root.

The ability to design RNA-based therapies to target specific genes makes them particularly attractive for treating rare genetic disorders, where conventional therapies are often limited. Several RNA-based therapeutics have already received regulatory approval, such as Patisiran (for hereditary transthyretin-mediated amyloidosis) and Nusinersen (for spinal muscular atrophy), demonstrating the clinical success and potential of RNA-based gene silencing therapies.

Segmental Insights

Product & Service Insights

Based on Product & Service, RNAi have emerged as the fastest growing segment in the Global Gene Silencing Market in 2024. One of the key drivers of RNAi's rapid growth is its wide range of therapeutic applications. RNAi-based treatments have shown significant promise in addressing a variety of conditions, including genetic disorders, cancers, and viral infections, where aberrant gene expression plays a critical role. The ability to directly target disease-related genes with high specificity, while minimizing off-target effects, has made RNAi a preferred option for developing novel treatments. This has led to an increase in research and clinical trials focused on RNAi therapies, accelerating market expansion.

Application Insights

Based on Application, Neurology have emerged as the fastest growing segment in the Global Gene Silencing Market during the forecast period. The global increase in neurological conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS) has driven the demand for innovative treatments. Gene silencing offers a promising therapeutic approach for addressing the underlying genetic causes of these neurodegenerative diseases, fueling growth in the neurology segment.

Download Free Sample Report

Regional Insights

Based on Region, North America have emerged as the dominating region in the Global Gene Silencing Market in 2024. North America is home to some of the world’s largest biotechnology and pharmaceutical companies, which have been pioneers in the development of gene-silencing technologies. Industry leaders such as Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Moderna are headquartered in the U.S., contributing to substantial research, development, and commercialization of RNA interference (RNAi), antisense oligonucleotides (ASOs), and other gene-silencing platforms. These companies have played a key role in advancing gene-silencing therapies, ensuring North America’s dominance in the market.

Recent Development

• In February 2025, Arrowhead Pharmaceuticals, Inc. commemorated Rare Disease Day by expanding its ‘We’ll Get There Soon’ campaign, which was originally launched for healthcare providers in November 2024. This phase includes the introduction of a dedicated educational website, www.LowerMyTGs.com, along with the Spotlight on FCS white paper. These resources offer vital support for individuals affected by Familial Chylomicronemia Syndrome (FCS), an ultra-rare genetic disorder that severely hinders the body's ability to process triglycerides. This results in dangerously elevated triglyceride (TG) levels—typically above 880 mg/dL—and significantly increases the risk of life-threatening conditions, such as acute pancreatitis. Given this risk, expert guidelines recommend keeping triglyceride levels below 500 mg/dL.
• In October 2024, biotechnology company Judo Bio launched with USD 100 million in Series A financing, led by Atlas Venture, TCG, and Droia Ventures. The company is dedicated to developing precision genetic medicines for the kidney, aimed at treating systemic and renal diseases. Judo Bio has pioneered a novel method for creating oligonucleotide therapies specifically designed for the kidney, an organ known for being particularly challenging for genetic medicines to reach. The company's proprietary STRIKE (Selectively Targeting RNA Into Kidney) platform enables the development of ligand-RNA conjugate drugs, which facilitate receptor-mediated uptake by specific kidney cell types, ultimately leading to gene silencing of disease-modifying target genes.
• In October 2024, researchers launched a new biotech company, Aptadir Therapeutics, with USD 1.6 million in pre-seed funding. The company aims to develop RNA-based therapies to reactivate specific genes silenced in cancer and genetic disorders such as fragile X syndrome. These therapies will leverage a new class of RNA molecules known as DNA methyltransferase-interacting inhibitors (DiRs), which can restore the function of targeted genes. The pre-seed funding was provided by EXTEND, an initiative of Italy's CDP Venture Capital, Angelini Ventures, and Evotec, which supports early-stage start-ups in transitioning discoveries from the lab to clinical applications.
• In December 2024, QIAGEN introduced Ingenuity Pathway Analysis (IPA) Interpret, a new feature aimed at simplifying and expediting the interpretation of complex biological data. By utilizing AI technology, IPA Interpret enables researchers to translate intricate differential expression analyses into actionable insights, facilitating a clearer understanding of which genes are implicated in diseases, biological processes, or responses to drugs or environmental conditions.

Key Market Players

• Revvity, Inc.
• Danaher Corporation
• Agilent Technologies, Inc.
• GenScript Biotech Corporation
• Merck KGaA
• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• New England Biolabs, Inc.

Report Scope

In this report, the Global Gene Silencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Gene Silencing Market, By Product & Service:

o   RNAi

o   CRISPR-Cas9

o   Antisense Oligonucleotides

o   Others

• Gene Silencing Market, By Application:

o   Neurology

o   Oncology

o   Infectious Diseases

o   Metabolic Diseases

o   Therapeutics Manufacturing

o   Others

• Gene Silencing Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Silencing Market.

Available Customizations:

Global Gene Silencing Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Gene Silencing Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com